Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

@article{Lavanchy2004HepatitisBV,
  title={Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures},
  author={Daniel Lavanchy},
  journal={Journal of Viral Hepatitis},
  year={2004},
  volume={11}
}
  • D. Lavanchy
  • Published 2004
  • Medicine
  • Journal of Viral Hepatitis
Summary.  Hepatitis B virus (HBV) infection is a serious global health problem, with 2 billion people infected worldwide, and 350 million suffering from chronic HBV infection. The 10th leading cause of death worldwide, HBV infections result in 500 000 to 1.2 million deaths per year caused by chronic hepatitis, cirrhosis, and hepatocellular carcinoma; the last accounts for 320 000 deaths per year [ 1, 2 ]. In Western countries, the disease is relatively rare and acquired primarily in adulthood… Expand
View on Wiley
ncbi.nlm.nih.gov
2,525 Citations
Highly Influential Citations
151
Background Citations
998
Methods Citations
28
Results Citations
17

Paper Mentions

Interventional Clinical Trial
Tenofovir Alafenamide in HBV Related Decompensated Liver
TAF is a new prodrug of tenofovir, specifically designed to achieve higher intracellular active drug concentration allowing for dosing of only 25 mg once daily and thus can… Expand
ConditionsHBV
InterventionDrug
Kaohsiung Medical University Chung-Ho Memorial Hospital
September 2020 - April 2025
Interventional Clinical Trial
A Randomized Controlled Trial on the Efficacy of Tenofovir Disoproxil Fumarate (TDF)-Switch Therapy in Chronic Hepatitis B Patients With Incomplete Response to Entecavir
Currently, five nucleos(t)ide analogs are approved for the treatment of chronic hepatitis B, namely lamivudine, adefovir dipivoxil, telbivudine, entecavir (ETV) and tenofovir disoproxil… Expand
ConditionsChronic Heptitis B
InterventionDrug
Chinese University of Hong Kong
August 2013 - January 2017
Interventional Clinical Trial
Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection
Randomized open-label substudy of daily Myrcludex B (MXB) plus pegylated interferon-alpha-2a (PEG-INF-a) in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B… Expand
ConditionsChronic Hepatitis D Infection
InterventionDrug
Hepatera Ltd.
February 2014 - January 2016
Interventional Clinical Trial
Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B
A randomized, open-label multicentre clinical trial of daily Myrcludex B versus entecavir in patients with HBeAg negative chronic hepatitis B.  
ConditionsChronic Hepatitis B
InterventionDrug
Hepatera Ltd.
November 2012 - October 2014

2,525 Citations

Citation Type

Citation Type

Epidemiology and Natural History of Chronic Hepatitis B Virus Infection
TLDR
The initiation of antiviral therapy in pregnant mothers with detectable virus can reduce the risk of perinatal HBV transmission when combined with vaccination and, where available, HBIG, and implementation of national vaccination programs has significantly decreased prevalence in multiple countries in both Asia and Africa. Expand
Global Epidemiology of Hepatitis B Virus (HBV) Infection
TLDR
There are remaining threats to the successful eradication of HBV worldwide, and expansion of national immunization programs with >80 % coverage globally has resulted in a steady decline in the prevalence, also focusing on transmission modes by region and specific preventative measures instituted. Expand
Toward elimination and eradication of hepatitis B
TLDR
The existing means to prevent and treat HBV infection render the goal toward eliminating and eradicating hepatitis B possible, although it will take much time and effort to achieve this objective. Expand
Treatment of Chronic Hepatitis B Virus Infection
TLDR
A systematic review of chronic HBV infection is designed to determine the successful treatment and following HBV positive patients and the distribution of HBV genotypes may guide us in determining disease burden. Expand
NATIONAL HEALTH POLICY CHALLENGE
TLDR
Bangladesh can be categorized as an intermediate endemic zone for HBV, despite an increased prevalence of HBV infection, the country has not incorporated hepatitis B vaccination into its national childhood immunization policy until recently, most probably because of its economic constraints. Expand
Epidemiology of chronic hepatitis viruses: hepatitis B virus and hepatitis C virus
TLDR
It is interesting to note that both viral infections can lead to liver inflammation, fibrosis, cirrhosis and hepatocellular carcinoma (HCC), and for HBV-infected individuals, an estimated 15-40% of patients with chronic infection will develop liver Cirrhosis leading to liver failure and possibly HCC. Expand
Prevention of hepatitis B virus infection by vaccination: Progress and problems
TLDR
Improvements in HB vaccine preparations have resulted in the development of safe and effective vaccine; anti-HBs seroconversion rate has been increased to >95% in people under 20 years of age and the WHO does not recommend the administration of booster injections at present, though future studies are needed. Expand
Hepatitis B virus infection
Since the introduction of the hepatitis B vaccine and other preventive measures, the worldwide prevalence of hepatitis B infection has fallen. However, chronic infection remains a challenging global… Expand
Hepatitis B and D
TLDR
For selected patients with decompensated liver cirrhosis due to HBV or HBV/HDV infection, liver transplantation may be appropriate and Interferon is the current accepted treatment option, though treatment results are disappointing. Expand
Chronic hepatitis B in children and adolescents.
TLDR
Safe and partially effective antiviral therapies are available, but few are licensed for use in children, and an accurate selection of subjects to treat and of the right timing for treatment is needed to optimize efficacy and reduce viral resistance. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 106 REFERENCES
Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection
  • F. Mahoney
  • Medicine
  • Clinical Microbiology Reviews
  • 1999
TLDR
Significant progress in the understanding of the molecular virology and pathogenesis of HBV infection has been made and effective treatment modalities have been developed for persons with chronic infection. Expand
Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium
TLDR
The objective of treating chronic HBV infection is to halt progression of liver injury by suppressing viral replication or eliminating infection by suppressing Viral replication and eliminating infection. Expand
Management of hepatitis B: 2000--summary of a workshop.
TLDR
This review provides a summary of a 3-day research workshop on September 8 ‐10, 2000 entitled “Management of Hepatitis B: 2000” and concluding recommendations on management of chronic hepatitis B. Expand
Development of recommendations for control of hepatitis B virus infections: the role of cost analysis.
TLDR
The results suggest the more widespread use of hepatitis B vaccine to prevent these high health-related costs and selected high risk group immunization of adults has not been successful in changing infection rates. Expand
Cost-effectiveness of Interferon-2b Treatment for Hepatitis B e Antigen-Positive Chronic Hepatitis B
TLDR
This study projected the expected clinical and economic outcomes of patients with chronic hepatitis B and estimated the cost-effectiveness of interferon therapy and calculated the quality-adjusted life expectancy for each cohort by using a Markov computer simulation. Expand
Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness.
TLDR
A significant reduction of acute viral hepatitis incidence and HBsAg carrier prevalence is found and the reduction in chronic sequelae of HBV pathology as an effect of the vaccination is found. Expand
Serologic and Clinical Outcomes of 1536 Alaska Natives Chronically Infected with Hepatitis B Virus
TLDR
The outcome of chronic HBV infection in this cohort is reported, including clearance rates of HBeAg and HBsAg, and the incidence of and risk factors associated with hepatocellular carcinoma and end-stage liver disease. Expand
Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination
TLDR
The vaccination coverage rate was defined as the percentage of children receiving at least three doses of HBV vaccine, and the vaccination histories of the studied population were assessed by examining their vaccination cards and by taking a history from their parents. Expand
Epidemiology of hepatitis B virus infection in the Asia–Pacific region
TLDR
There has been a decrease in the prevalence of HBV infection after mass HBV vaccination programmes in some Asia– Pacific countries, which may be due to the intervention of possible transmission routes through the use of disposable syringes and needles, and prevention of high‐risk tattooing, acupuncture, ear‐piercing and sexual contact. Expand
A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers.
TLDR
It is concluded that a mass hepatitis B vaccination program is feasible in hyperendemic areas such as Taiwan; this should be a significant step toward the effective control of HBV infection in these areas. Expand
...
1
2
3
4
5
...